In one of the latest studies, researchers from Iran analyzed the impact of a proprietary formula containing plant-based CBD and THC in a 10:1 ratio, which was created by Yas Daru, a pharmaceutical firm in Tehran. It was given to 50 diabetic patients diagnosed with type 2 diabetes sublingually to help keep glucose as well as cholesterol levels in check. The study participants administered the sublingual spray twice a day for 8 weeks.